利伐沙班拜瑞妥图片及介绍

Xarelto is an anticoagulant drug. It is a new type of oral anticoagulant that inhibits coagulation factor X. There is no need to monitor coagulation, it has a relatively long action time, and reduces the risk of bleeding for patients. It is a very safe drug, and its clinical efficacy is very reliable. Today let’s take a detailed look at the pictures and introduction of Rivaroxaban Xarelto.

Rivaroxaban is available as red film-coated tablets. Its main active ingredient is: Rivaroxaban, a highly selective oral drug that directly inhibits factor Xa. Clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery.

For patients who undergo major hip surgery, the clinically recommended treatment course is 5 weeks of treatment, which means that such patients generally need to take Rivaroxaban Xarelto for 5 weeks for one course of treatment; while for patients who undergo major knee surgery, the clinically recommended treatment course is 2 weeks of treatment, which means that such patients generally need to take Rivaroxaban for 2 weeks for one course of treatment. If the patient misses medication during this period, he should take rivaroxaban as soon as possible, and then continue the previously recommended usage the next day, that is, take the medication once a day.

A study published in the Journal of Thrombosis shows that monotherapy with the new oral anticoagulant rivaroxaban Xarelto in Chinese patients can effectively treat deep vein thrombosis and pulmonary embolism and prevent their subsequent recurrence. The study randomly assigned Chinese patients to two groups: oral rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) or standard therapy (injectable enoxaparin bridged with a dose-adjusted vitamin K antagonist) for 3, 6, or 12 months.

The results showed that the two treatments were equally effective in treating acute symptomatic deep vein thrombosis and/or symptomatic pulmonary embolism, and the rivaroxaban group had a lower rate of major bleeding. In addition, the study also found that rivaroxaban Xarelto has similar efficacy in high-risk groups, such as elderly or frail patients, patients with kidney damage, cancer patients, and patients with larger clots in the body. Furthermore, rivaroxaban was well tolerated by Chinese patients and did not require routine coagulation monitoring, dose adjustments, or dietary restrictions.

The above is the content introduced by Xarelto, I hope it can help you!

Recommended related hot articles: /newsDetail/83297.html